Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China
Executive Summary
Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.
You may also be interested in...
JHL Biotech Executives Convicted Over Trade Secrets Theft
Two former JHL Biotech executives, Racho Jordanov and Rose Lin, have been convicted in the US of conspiracy to commit trade secret theft and wire fraud after submitting plea agreements. Meanwhile, the company – now named Eden Biologics – has just announced a change of CEO.
Former JHL Executives Charged Over Trade Secrets Theft And Fraud
Two former JHL Biotech executives, co-founders Racho Jordanov and Rose Lin, have been accused of a “fraudulent scheme to steal thousands of confidential and proprietary documents from Genentech” to help the firm accelerate its development and production of biosimilars.
New $350m Site To Build Pfizer’s China Biosimilar Capacity
While some multinationals appear concerned about China's slowing economy and their business prospects in this market, others are forging ahead with major new investments, including Pfizer, which has just unveiled plans for a large biosimilars production and R&D site.